Clinics & Centers

Sinonasal Soft Tissue Sarcoma Subspecialty

Soft tissue sarcoma is a rare group of heterogeneous solid tumors derived from mesenchymal cells. It accounts for 1% of all adult malignant tumors and 15% of children’s malignant tumors. 9% of them occur in the head and neck. Soft tissue sarcoma in the nasal cavity, sinuses and skull base is even rarer. Nasal skull base surgical team in Eye & ENT Hospital affiliated to Fudan University diagnoses and treats more than 60 cases of soft tissue sarcoma in nasal cavity and paranasal sinus each year. The relevant retrospective research results have been published in renowned periodicals such as J Cancer Res Clin Oncol, Auris Nasus Larynx, and the Chinese Journal of Otorhinolaryngology Head and Neck Surgery.

 

At present, surgical resection is a very important treatment method for patients with nasal cavity and paranasal sinus soft tissue sarcoma. The goal of surgery is not only to completely remove the tumor, but also to obtain a safe surgical margin. This is a great challenge for curing soft tissue sarcomas that occur at the base of the nose and skull. The nasal skull base surgery team of our hospital is in a leading position in this field, via our in-depth anatomical research, advanced hardware equipment, ultra-high surgical technology and experienced perioperative management.

 

At present, there is still a lack of high-quality clinical studies related to nasal cavity and sinus soft tissue sarcoma, and many urgent questions are waiting for us to conquer. Therefore, Fudan EENT formally established Fudan EENT Sinonasal Soft Tissue Sarcoma Subspecialty in April 2021. The subspecialty is headed by Xue Kai-a young skull base surgeon,with the guidance of Professor Wang Dehui and Professor Yu Hongmeng. The key members include otolaryngology experts and neurosurgery experts from the nasal skull base surgical team in Fudan EENT, with a team of multidisciplinary diagnosis and treatment as a strong support. We are committed to in-depth research on the treatment of nasal cavity and paranasal sinus soft tissue sarcoma, for improving the treatment outcome and improving the diagnosis and treatment schemes, which ultimately benefit patients.


返回上一步